Filtered By:
Management: Food and Drug Administration (FDA)
Countries: Mexico Health

This page shows you your search results in order of date.

Order by Relevance | Date

Total 18 results found since Jan 2013.

News at a glance: New U.S. coronavirus research, lab gear ’s carbon cost, and a repurposed accelerator
MATERIALS SCIENCE Storied accelerator to test chips The world’s first superconducting cyclotron will receive a new lease on life testing next-generation microchips, Michigan State University’s Facility for Rare Isotope Beams (FRIB) announced last week. From 1982 to 2020, the K-500 cyclotron produced beams of atomic nuclei ranging from hydrogen to uranium for experiments in nuclear physics, relying on superconducting magnets to confine the particles. Last year, the cyclotron was replaced by FRIB’s new, more powerful, $730 million linear accelerator. Typically, old particle accelerators are demolished or...
Source: Science of Aging Knowledge Environment - April 13, 2023 Category: Geriatrics Source Type: research

Second Phase of the NIH Preprint Pilot Launched
Today, we are pleased to announce the launch of the second phase of the NIH Preprint Pilot with the addition of more than 700 new preprint records to PubMed Central (PMC) and PubMed. This second phase expands the scope of the Pilot to include preprints resulting from all NIH-funded research. Eligible preprints are those acknowledging direct support of an NIH award or authored by NIH staff and posted to bioRxiv, medRxiv, arXiv, or Research Square, on or after January 1, 2023. NLM will automatically include the full text of the preprint (as license terms allow) and associated citation information in PMC and PubMed, respectiv...
Source: PubMed Central News - January 30, 2023 Category: Databases & Libraries Source Type: news

Next Phase of NIH Preprint Pilot Launching Soon
Last month, the National Library of Medicine (NLM)announced plans to extend its NIH Preprint Pilot in PubMed Central (PMC) and PubMed beyond COVID-19 to encompass all preprints reporting on NIH-funded research. The second phase of the pilot, launching later this month, will include preprints supported by an NIH award, contract, or intramural program and posted to aneligible preprint server on or after January 1, 2023.In preparation for the launch of this second phase, we have updated PMC and PubMed site features to help users of these databases incorporate the increased volume of preprints into their discovery workflows. S...
Source: PubMed Central News - January 10, 2023 Category: Databases & Libraries Source Type: news

A Fourth COVID-19 Vaccine, From Novovax, Passed a Key Stage in the Authorization Process
American adults who haven’t yet gotten vaccinated against COVID-19 may soon get another choice, as advisers to the Food and Drug Administration on Tuesday backed a more traditional type of shot. Next, the FDA must decide whether to authorize the protein vaccine made by latecomer Novavax as the nation’s fourth coronavirus shot for adults. It’s made with more conventional technology than today’s dominant Pfizer and Moderna shots and the lesser-used Johnson & Johnson option. Novavax shots are already available in Australia, Canada, parts of Europe and multiple other countries, either for initial va...
Source: TIME: Health - June 8, 2022 Category: Consumer Health News Authors: LAURAN NEERGAARD / AP Tags: Uncategorized COVID-19 healthscienceclimate wire Source Type: news

FDA Advisers Back a New COVID-19 Vaccine, Made By Novavax
American adults who haven’t yet gotten vaccinated against COVID-19 may soon get another choice, as advisers to the Food and Drug Administration on Tuesday backed a more traditional type of shot. Next, the FDA must decide whether to authorize the vaccine made by latecomer Novavax, a protein vaccine that’s made with a more conventional technology than today’s U.S. options. Novavax shots are already used in Australia, Canada, parts of Europe and dozens of other countries. But U.S. clearance is a key hurdle for the Maryland-based company. FDA’s vaccine chief Dr. Peter Marks said another choice in the U....
Source: TIME: Health - June 7, 2022 Category: Consumer Health News Authors: Lauran Neergaard / AP Tags: Uncategorized COVID-19 wire Source Type: news

‘The Window is Closing’: White House Warns U.S. Faces New COVID-19 Risk Without More Shots
WASHINGTON (AP) — White House COVID-19 coordinator Dr. Ashish Jha issued a dire warning Thursday that the U.S. will be increasingly vulnerable to the coronavirus this fall and winter if Congress doesn’t swiftly approve new funding for more vaccines and treatments. In an Associated Press interview, Jha said Americans’ immune protection from the virus is waning, the virus is adapting to be more contagious and booster doses for most people will be necessary—with the potential for enhanced protection from a new generation of shots. His warning came as the White House said there could be up to 100 millio...
Source: TIME: Health - May 13, 2022 Category: Consumer Health News Authors: ZEKE MILLER / AP Tags: Uncategorized COVID-19 overnight wire Source Type: news

Biden to Double Free COVID-19 Tests and Provide N95s to Fight Omicron
(Washington D.C.) — President Joe Biden announced Thursday that the government will double to 1 billion the rapid, at-home COVID-19 tests to be distributed free to Americans, along with the most protective N95 masks, as he highlighted his efforts to “surge” resources to help the country weather the spike in coronavirus cases. Biden also announced that starting next week 1,000 military medical personnel will begin deploying across the country to help overwhelmed medical facilities ease staff shortages due to the highly transmissible omicron variant. Many facilities are struggling because their workers are ...
Source: TIME: Health - January 13, 2022 Category: Consumer Health News Authors: Zeke Miller / AP Tags: Uncategorized COVID-19 healthscienceclimate News Desk wire Source Type: news

Are the Allergic Reactions of COVID-19 Vaccines Caused by mRNA Constructs or Nanocarriers? Immunological Insights
AbstractThe Food and Drug Administration (FDA) has recently authorized the two messenger RNA (mRNA) vaccines BNT162b2 and mRNA-1273 for emergency use against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing the COVID-19 coronavirus disease. BNT162b2 and mRNA-1273 vaccines were developed by Pfizer-BioNTech and Moderna, respectively, in 2020. The United Kingdom, Bahrain, Canada, Mexico, United States, Singapore, Oman, Saudi Arabia, Kuwait, and European Union began their vaccination programs with the BNT162b2 vaccine, while the United States and Canada also started the mRNA-1273 vaccination program in ...
Source: Interdisciplinary Sciences, Computational Life Sciences - May 22, 2021 Category: Bioinformatics Source Type: research

Biden Plans to Share 20 Million More COVID-19 Vaccine Doses With Rest of World
WASHINGTON — President Joe Biden said Monday that the U.S. will share an additional 20 million doses of COVID-19 vaccines with the world in the coming six weeks as domestic demand for shots drops and global disparities in distribution have grown more evident. The doses will come from existing production of Pfizer, Moderna or Johnson & Johnson vaccine stocks, marking the first time that U.S.-controlled doses of vaccines authorized for use in the country will be shared overseas. It will boost the global vaccine sharing commitment from the U.S. to 80 million. “We know America will never be fully safe until the...
Source: TIME: Health - May 17, 2021 Category: Consumer Health News Authors: Associated Press Tags: Uncategorized COVID-19 Source Type: news

Johnson & Johnson Single-Shot COVID-19 Vaccine Phase 3 Data Published in New England Journal of Medicine
NEW BRUNSWICK, N.J., April 21, 2021 – Johnson & Johnson (the Company) today announced publication in the New England Journal of Medicine of primary data from the Phase 3 ENSEMBLE clinical trial for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen). The publication of the primary analysis follows the topline efficacy and safety data announced in January, showing the trial met all primary and key secondary endpoints, and found that the Johnson & Johnson single-dose COVID-19 vaccine prevented hospitalization and death across all study participants ...
Source: Johnson and Johnson - April 21, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

PNR Weekly Digest: March 30, 2021
Items regarding COVID-19 information are indicated with an * In the Dragonfly: *NNLM Covid-19 Symposium. Keynote Speakers Announced. Registration is Open The Network of the National Library of Medicine (NNLM) is excited to announce a new, free virtual symposium focused on addressing the COVID-19 infodemic in our communities. The NNLM Virtual Symposium: Responding to the COVID-19 Infodemic is an opportunity to address misinformation and mistrust, raise awareness about the pandemic, and efforts to combat it. Symposium attendees can expect to come away from the 2-day experience with a better understanding of COVID-19 and shar...
Source: Dragonfly - March 30, 2021 Category: Databases & Libraries Authors: Carolyn Martin Tags: PNR Weekly Digest Source Type: news

Covid-19 Deaths: 1 Million and Surging
Face masks hanging on window bars in Havana, Cuba. Credit: Jorge Luis Baños/IPS By Joseph ChamieNEW YORK, Oct 1 2020 (IPS) Covid-19 deaths worldwide have surpassed 1 million. With new cases of coronavirus infections rapidly mounting again, the numbers of Covid-19 deaths are feared to surge in the coming months.  It took approximately 40 weeks to reach the first million Covid-19 recorded deaths. Some have projected the second million Covid-19 deaths to take about 10 weeks, arriving in late December, and the third million to take an additional 4 weeks, arriving in late January. Approximately 60 percent of the 1 million Cov...
Source: IPS Inter Press Service - Health - October 1, 2020 Category: International Medicine & Public Health Authors: Joseph Chamie Tags: Global Headlines Health TerraViva United Nations COVID-19 Source Type: news

Johnson & Johnson ’ s Coronavirus Vaccine Enters Phase 3 Trial With Beth Israel
cbsoptanon.onScriptsReady(function(cmp){cmp.ot.targetingAllowed(function(a){if(a) AnvatoPlayer("p1").init({"mcp":"cbs","width":"100%","height":"100%","video":"4730668","autoplay":false,"titleVisible":false,"accessKey":"EZqvRyKE7qmqDflDPXIw6U7kKZEA0Vx7","accessControl":{"preview":false},"pInstance":"p1","plugins":{"heartbeat":{"account":"cbslocal-global-unified","publisherId":"cbslocal","jobId":"sc_va","marketingCloudId":"823BA0335567497F7F000101@AdobeOrg","trackingServer":"cbsdigitalmedia.hb.omtrdc.net","customTrackingServer":"cbsdigitalmedia.d1.sc.omtrdc.net","chapterTracking":false,"version":"1.5"},"comscore":{"clientId"...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - September 23, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Covid-19 Boston, MA Health Healthcare Status Beth Israel Deacones Medical Center Coronavirus Johnson & Johnson Source Type: news

Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen ’s COVID-19 Vaccine Candidate
NEW BRUNSWICK, N.J., September 23, 2020 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, JNJ-78436735, being developed by its Janssen Pharmaceutical Companies. The initiation of the ENSEMBLE trial follows positive interim results from the Company’s Phase 1/2a clinical study, which demonstrated that the safety profile and immunogenicity after a single vaccination were supportive of further development. These results have been submitted to medRxiv and are due to be published online imminentl...
Source: Johnson and Johnson - September 23, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news